10,172 results match your criteria Acromegaly


Contemporary issues in pituitary disease: case-based management update.

Expert Rev Endocrinol Metab 2009 Jul;4(4):317-320

c Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A53, Cleveland, OH 44195, USA.

Since 2005, the Cleveland Clinic Foundation has held an annual symposium addressing contemporary issues in pituitary disease. The faculty includes Cleveland Clinic Foundation staff, physicians and invited specialists, and the presentations are case-based with frequent audience response in order to be of real value in terms of the issues that may occur in day-to-day clinical practice relating to pituitary disease. This brief meeting report summarizes the key points arising from this interactive format. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.09.18DOI Listing

Targeting growth hormone function: strategies and therapeutic applications.

Signal Transduct Target Ther 2019 8;4. Epub 2019 Feb 8.

1Liggins Institute, University of Auckland, Auckland, New Zealand.

Human growth hormone (GH) is a classical pituitary endocrine hormone that is essential for normal postnatal growth and has pleiotropic effects across multiple physiological systems. GH is also expressed in extrapituitary tissues and has localized autocrine/paracrine effects at these sites. In adults, hypersecretion of GH causes acromegaly, and strategies that block the release of GH or that inhibit GH receptor (GHR) activation are the primary forms of medical therapy for this disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41392-019-0036-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367471PMC
February 2019

ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly.

Endocrinol Diabetes Nutr 2019 Feb 14. Epub 2019 Feb 14.

Endocrinology Department, Hospital General Universitario de Alicante-ISABIAL-FISABIO, Alicante, Spain.

Objectives: The ACROSTART study was intended to determine the time to achieve normalization of GH and IGF-I levels in responding patients with acromegaly administered different dosage regimens of lanreotide Autogel (Somatuline Autogel).

Methods: From March 2013 to October 2013, clinical data from 57 patients from 17 Spanish hospitals with active acromegaly treated with lanreotide for ≥4 months who achieved hormonal control (GH levels <2.5ng/ml and/or normalized IGF-I levels in ≥2 measurements) were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.endinu.2018.12.004DOI Listing
February 2019

First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy.

Growth Horm IGF Res 2019 Feb 3;45:17-19. Epub 2019 Feb 3.

Department of Human Pathology 'G.Barresi', University of Messina, Italy.

The GH-receptor antagonist pegvisomant (PEG) reduces peripheral IGF-1 synthesis and is used to treat acromegaly patients resistant or intolerant to somatostatin analogues (SSA). Medical therapy is generally life-long in patients with acromegaly, since disease remission is very uncommon after SSA discontinuation and has never been reported after PEG withdrawal. Here, we report for the first time the cases of two acromegaly patients treated with PEG monotherapy for many years because of resistance to SSA, who persistently maintained normal serum IGF-1 levels after PEG withdrawal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ghir.2019.02.001DOI Listing
February 2019

Evidence of Pituitary Tumor and Acromegaly in an Ancient Egyptian Mummy Head.

Rofo 2019 Feb 14. Epub 2019 Feb 14.

Reiss-Engelhorn-Museen Mannheim, German Mummy Project, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0851-6798DOI Listing
February 2019

Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study.

Pituitary 2019 Feb 13. Epub 2019 Feb 13.

Pfizer S.L.U, Avda. Europa, 20B. Parque Empresarial La Moraleja, 28108, Alcobendas, Madrid, Spain.

Purpose: The burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been previously studied. This study was aimed to determine the adherence to pegvisomant treatment in acromegaly patients in the real-world clinical practice setting in Spain.

Methods: Multicenter, observational, descriptive, cross-sectional study in patients with acromegaly treated with pegvisomant for at least 12 months. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11102-019-00943-1
Publisher Site
http://dx.doi.org/10.1007/s11102-019-00943-1DOI Listing
February 2019
1 Read

The effect of disease activity on thyroid nodules in patients with acromegaly.

Endocr J 2019 Feb 9. Epub 2019 Feb 9.

Department of Endocrinology and Metabolism, Diskapi Teaching and Research Hospital, Ankara, Turkey.

Nodular thyroid disease is a very common disorder in patients with acromegaly. Insulin-like growth factor-1 (IGF-1) is a thyroid growth factor, and there is a correlation between IGF-1 levels and thyroid volume (TV) in patients with acromegaly. There is no study investigating the impact of somatostatin analog (SSA) treatment on thyroid nodule volume in patients with acromegaly. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub
Publisher Site
http://dx.doi.org/10.1507/endocrj.EJ18-0502DOI Listing
February 2019
7 Reads

Acromegaly associated with GIST, non-small cell lung cancer, clear cell renal cancer, myeloma multiplex, medulla oblongata tumor, adrenal adenoma and follicular thyroid nodules.

Endokrynol Pol 2019 Feb 11. Epub 2019 Feb 11.

Dept. of Endocrinology, Diabetes and Isotope Therapy, Medical University Wroclaw, Pasteura 4, 50-367 Wrocłąw, Poland.

Background: Acromegaly is associated with increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion which may support tumor development and growth.

Case Presentation: A 68-year old woman was diagnosed with acromegaly due to typical clinical and hormonal characteristics. While a contrast-enhanced MRI at diagnosis did not reveal a pituitary adenoma, a 5 mm lesion was identified on repeat scanning 13 months later. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/EP.a2019.0005DOI Listing
February 2019
5 Reads

Acromegaly in the era of precision medicine.

Authors:
Antonio Pico

Minerva Endocrinol 2019 Feb 6. Epub 2019 Feb 6.

Department of Endocrinology and Nutrition, General University Hospital of Alicante - iSaBial, Miguel Hernández University, CIBERER, Alicante, Spain -

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0391-1977.19.02972-9DOI Listing
February 2019

The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas.

Growth Horm IGF Res 2019 Jan 30;45:1-5. Epub 2019 Jan 30.

Department of Neurosurgery, Kocaeli University Faculty of Medicine, Umuttepe Kocaeli, Turkey.

Purpose: Somatostatin analogues (SSAs) can slow down the growth of neuroendocrine tumors. However, the mechanism remains unclear. Recent studies on patients with acromegaly suggest that SSAs may induce apoptosis, increase autophagy, and decrease cell proliferation of pituitary adenoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ghir.2019.01.001DOI Listing
January 2019

Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.

Sci Rep 2019 Feb 4;9(1):1122. Epub 2019 Feb 4.

Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Filamin-A (FLNA) plays a crucial role in somatostatin receptor (sst) subtype-2 signaling in somatotropinomas. Our objective was to investigate the in vivo association between FLNA and sst2 expression, sst5 expression, dopamine receptor subtype-2 (D2) expression, somatostatin receptor ligand (SRL) responsiveness and tumor invasiveness in somatotropinomas. Quantitative real-time PCR was used to evaluate the absolute mRNA copy numbers of FLNA/sst2/sst5/D2 in 96 somatotropinomas. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-37692-3
Publisher Site
http://dx.doi.org/10.1038/s41598-018-37692-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361919PMC
February 2019
2 Reads

Long-term effects of intracapsular debulking and adjuvant somatostatin analogs for growth hormone-secreting pituitary macroadenoma: 10 years of experience in a single institute.

World Neurosurg 2019 Feb 1. Epub 2019 Feb 1.

Department of Minimally Invasive Skull Base Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Physical Therapy, Hung Kuang University, Taichung, Taiwan. Electronic address:

Objective: Long-term effects of endoscopic endonasal transsphenoidal intracapsular debulking and adjuvant somatostatin analogs were evaluated in patients with growth hormone secreting pituitary macroadenomas.

Methods: We retrospectively reviewed the medical records of 45 patients with acromegalic macroadenoma who underwent endonasal endoscopic transsphenoidal intracapsular debulking and received adjuvant somatostatin analogs (octreotide) between 2006 and 2015, who had more than 1 year of follow-up. To evaluate the predictive factors for 1 year and long-term biochemical outcomes, univariate and multivariate analyses were performed. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750193022
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2019.01.125DOI Listing
February 2019
3 Reads

Mutations in GPR101 as a potential cause of X-linked acrogigantism and acromegaly.

Prog Mol Biol Transl Sci 2019 23;161:47-67. Epub 2018 Nov 23.

Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States; Center for Neuroscience Initiative, Auburn University, Auburn, AL, United States. Electronic address:

X-linked acrogigantism (XLAG) is a recently described early-onset gigantism due to GPR101 duplication that induces growth hormone (GH) oversecretion. GPR101, which belongs to Family A rhodopsin-like family of G protein-coupled receptors, is predominantly expressed in hypothalamus and pituitary, suggesting that GPR101 might be important in regulating diverse functions such as energy balance and reproduction. Most mammalian GPR101s have extremely long third intracellular loops (ICL3); however, zebrafish GPR101 has a much shorter ICL3, but a longer C-terminus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.pmbts.2018.10.003DOI Listing
November 2018
1 Read

Prevalence and risk factors of sleep breathing disorders in patients with acromegaly from Moscow region.

Ter Arkh 2018 Nov;90(10):65-70

Moscow Regional Research and Clinical Institute («MONIKI»), Moscow, Russia.

Aim: Assessment of prevalence and risk factors of sleep breathing disorders in patients with acromegaly from Moscow region.

Materials And Methods: Cardiorespiratory monitoring was executed to 55 patients with acromegaly (18 men and 37 women): 27 patients with de novo disease, 28 patients on treatment of acromegaly (including 18 patietns with uncontrolled and 10 - with controlled acromegaly). All subgroups did not differ on sex, BMI and age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh2018901065-70DOI Listing
November 2018
1 Read

An update on clinical care for pregnant women with acromegaly.

Expert Rev Endocrinol Metab 2019 Jan 17:1-12. Epub 2019 Jan 17.

d Service d'Endocrinologie et des Maladies Métaboliques , Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey , Toulouse , France.

Introduction: As pregnancy is rare in women with acromegaly, only case reports and few series have been published. Areas covered: All case reports and publications dealing with pregnancy in patients with acromegaly were collated. Information concerning the effects of acromegaly on pregnancy outcomes, the impact of pregnancy on GH/IGF-I measurements, acromegaly comorbidity and pituitary adenoma size, the effects of treatment of acromegaly on fetus outcomes were retrieved and analyzed. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17446651.2019.1
Publisher Site
http://dx.doi.org/10.1080/17446651.2019.1571909DOI Listing
January 2019
9 Reads

Growth hormone response to oral glucose load: from normal to pathological conditions.

Neuroendocrinology 2019 Jan 25. Epub 2019 Jan 25.


The exact physiological basis of acute GH suppression by oral glucose is not fully understood. Glucose-mediated increase in hypothalamic somatostatin seems to be the most plausible explanation. Attempts to better understand its underlying mechanisms are compromised by species disparities in the response of GH to glucose load. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497214DOI Listing
January 2019
1 Read

An uncommon cause of acute abdomen in an acromegalic patient: colonic volvulus.

Ann Ital Chir 2018 ;89:572-576

Acromegaly is a chronic endocrine disease, typically caused by a pituitary adenoma leading to increased circulating GH levels and increased IGF-I secretion by peripheral tissues. Gastrointestinal diseases related acromegaly such as colon cancers, adenomatous polyps, and dolichocolon are much less known. We aimed to present a case of complete colonic volvulus in a patient with acromegaly. Read More

View Article

Download full-text PDF

Source
January 2018
3 Reads

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control.

Int J Endocrinol 2018 19;2018:5421961. Epub 2018 Dec 19.

Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine (DIBIMIS), University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy.

Objective: In acromegaly, both lipotoxicity secondary to GH excess and insulin resistance have a significant impact on the liver. Ultrasonography has shown poor sensitivity in detecting hepatic steatosis and noninvasive methods have been proposed. We evaluated the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, and we correlated it with disease activity and insulin resistance. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/ije/2018/5421961/
Publisher Site
http://dx.doi.org/10.1155/2018/5421961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313980PMC
December 2018
4 Reads

PREDICTIVE MARKERS FOR POST-SURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE.

Endocr Pract 2019 Jan 18. Epub 2019 Jan 18.

Western University, London, ON, Canada.

Objective: To clarify selection of medical therapy following transsphenoidal surgery in patients with acromegaly, based on growth hormone/insulin like growth factor -1 (GH/IGF-1) response and glucometabolic control.

Methods: We carried out a systematic literature review on three of the best studied and most practical predictive markers of somatostatin analogues (SSA) response: somatostatin receptor (SSTR) expression, tumor morphologic classification, and T2-weighted MRI signal intensity. Additional analyses focused on glucose metabolism in treated patients. Read More

View Article

Download full-text PDF

Source
http://journals.aace.com/doi/10.4158/EP-2018-0500
Publisher Site
http://dx.doi.org/10.4158/EP-2018-0500DOI Listing
January 2019
5 Reads

Executive functioning and quality of life in acromegaly.

Psychol Res Behav Manag 2019 3;12:39-44. Epub 2019 Jan 3.

Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania,

Introduction: Active acromegaly is a rare chronic endocrine disorder caused by excessive growth hormone (GH). Clinical studies suggest that cognitive performance is impaired in acromegaly - particularly executive function as well as short- and long-term memory. This study compared the quality of life (QoL) and executive functioning in acromegaly patients vs healthy controls. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/executive-functioning-and-quality-
Publisher Site
http://dx.doi.org/10.2147/PRBM.S183950DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322494PMC
January 2019
8 Reads

Elastography detected solid organ stiffness increased in patients with acromegaly.

Medicine (Baltimore) 2019 Jan;98(3):e14212

Department of Internal Medicine.

Elastography is a method to examine the increase in solid organs stiffness (SOS), and there is no data in the literature regarding to its use in patients with acromegaly. In this study, we aimed to investigate the change of SOS in patients with acromegaly and to determine the parameters closely related to SOS in same patient groups.We included 40 subjects with acromegaly and 40 healthy control subjects. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201901180-0009
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000014212DOI Listing
January 2019
3 Reads

Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors.

Minerva Endocrinol 2019 Jan 16. Epub 2019 Jan 16.

Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain -

Acromegaly is a chronic systemic disease mainly caused by a growth hormone (GH)- secreting pituitary neuroendocrine tumor (PitNETs), which is associated with many health complications and increased mortality when not adequately treated. Transsphenoidal surgery is considered the treatment of choice in GH-secreting PitNETs, but patients in whom surgery cannot be considered or with persistent disease after surgery require medical therapy. Treatment with available synthetic somatostatin analogues (SSAs) is considered the mainstay in the medical management of acromegaly which exert their beneficial effects through the binding to a family of G-protein coupled receptors encoded by 5 genes (SSTR1- 5). Read More

View Article

Download full-text PDF

Source
https://www.minervamedica.it/index2.php?show=R07Y9999N00A190
Publisher Site
http://dx.doi.org/10.23736/S0391-1977.19.02970-5DOI Listing
January 2019
6 Reads

Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology.

Onco Targets Ther 2019 31;12:319-339. Epub 2018 Dec 31.

Department of Urology, Agios Savvas Cancer Hospital, Athens 11522, Greece,

Pleiotropy in biological systems and their targeting allows many pharmaceuticals to be used for multiple therapeutic purposes. Fully exploiting the therapeutic properties of drugs that are already marketed would be highly advantageous. This is especially the case in the field of oncology, where the ineffectiveness of typical anticancer agents is a common issue, while the development of novel anticancer agents is a costly and particularly time-consuming process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S182685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317484PMC
December 2018
2 Reads
1.342 Impact Factor

Nonparathyroid Hypercalcemia.

Authors:
David Goltzman

Front Horm Res 2019 19;51:77-90. Epub 2018 Nov 19.

Primary hyperparathyroidism is among the most common causes of hypercalcemia. However, ingestion of medication, including hydrochlorathiazide, lithium, and foscarnet, excessive vitamin A ingestion, endocrinopathies such as hyperthyroidism, adrenal insufficiency, and acromegaly, abnormal nutrient intake such as parenteral nutrition in preterm infants and milk-alkali syndrome, and prolonged immobilization have all been associated with hypercalcemia. The most common cause of nonparathyroid hypercalcemia is neoplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491040DOI Listing
November 2018
2 Reads

Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly.

Endocr Connect 2019 Jan;8(1):39-49

Endocrinology/Medicine Department, Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), IIB-Sant Pau, ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Background Biochemical control of GH/IGF-I excess in acromegaly (ACRO) is associated with persistent impairment of trabecular microstructure leading to increased risk of vertebral fractures. Circulating miRNAs modulate the activity of osteoblasts and osteoclasts, and may be potential biomarkers of osteoporosis. Aims Identify differentially expressed miRNAs in the serum of patients with controlled ACRO vs controls and correlate miRNA levels with both biochemical and structural bone parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-18-0482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330718PMC
January 2019
2 Reads

Three Novel MEN1 Variants in AIP-Negative Familial Isolated Pituitary Adenoma Patients.

Pathobiology 2019 Jan 10:1-7. Epub 2019 Jan 10.

Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Objectives: Pituitary adenomas (PAs) may rarely occur in well-defined hereditary conditions, like multiple endocrine neoplasia type 1 (MEN1) syndrome and familial isolated pituitary adenoma (FIPA) associated with germline mutations in MEN1 and AIP, respectively. This study aimed to assess MEN1 genetic abnormalities in AIP mutation-negative FIPA patients, not associated with MEN1 components.

Methods: Among 20 patients evaluated in 13 FIPA families, 12 were previously reported as AIP mutation-negative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495252DOI Listing
January 2019
3 Reads

Immediate Use of Continuous Positive Airway Pressure in Patients With Obstructive Sleep Apnea Following Transsphenoidal Pituitary Surgery: A Case Series.

J Neurosurg Anesthesiol 2019 Jan 8. Epub 2019 Jan 8.

Department of Anesthesiology and Perioperative Care, Vancouver General Hospital.

Background: Patients who undergo transsphenoidal pituitary resection have an elevated risk of obstructive sleep apnea (OSA) yet their outcomes and the safety of continuous positive airway pressure (CPAP) remains unclear. Our study objective was to determine the incidence of complications related to the use of early positive airway pressure following pituitary resection.

Methods: We retrospectively identified all patients who underwent endoscopic transsphenoidal pituitary tumor resection between January 1, 2005 and March 24, 2016 at our institution, including those with diagnosed or suspected OSA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ANA.0000000000000573DOI Listing
January 2019
4 Reads

AcroVoice: eliciting the patients' perspective on acromegaly disease activity.

Pituitary 2019 Feb;22(1):62-69

Pfizer Canada Inc, Rare Disease Medical Affairs, Kirkland, QC, Canada.

Purpose: To determine how patients define acromegaly disease activity and treatment success and to quantify from the patients' perspective the relative importance of each disease parameter included in the ACRODAT®.

Methods: One hundred acromegaly patients on medical therapy (mean age = 47.1 years; SD = 11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11102-018-00933-9DOI Listing
February 2019
2 Reads

Pregnancy in Acromegaly is safe and is associated with improvements in GH/IGF-1 concentrations.

Eur J Endocrinol 2019 Jan 1. Epub 2019 Jan 1.

M Sherlock, Academic Department of Diabetes and Endocrinology, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland.

Pregnancy is rarely reported in acromegaly. Many patients are diagnosed in later life and younger patients may have subfertility due to hypopituitarism. We present a case series of 17 pregnancies in 12 women with acromegaly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EJE-18-0688DOI Listing
January 2019
1 Read

Pituitary Pathology and Gene Expression in Acromegalic Cats.

J Endocr Soc 2019 Jan 16;3(1):181-200. Epub 2018 Oct 16.

Diabetic Remission Clinic, Department of Clinical Science and Services, Royal Veterinary College, North Mymms, United Kingdom.

The prevalence of GH-secreting pituitary tumors in domestic cats () is 10-fold greater than in humans. The predominant inhibitory receptors of GH-secreting pituitary tumors are somatostatin receptors (SSTRs) and D dopamine receptor (DRD2). The expression of these receptors is associated with the response to somatostatin analog and dopamine agonist treatment in human patients with acromegaly. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jes/article/3/1/181/5128914
Publisher Site
http://dx.doi.org/10.1210/js.2018-00226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316999PMC
January 2019
3 Reads

Influence of the -202A/C Gene Polymorphism on Clinical Features and Surgery Outcome in Acromegalic Patients.

Front Endocrinol (Lausanne) 2018 11;9:751. Epub 2018 Dec 11.

Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Excess growth hormone (GH) secretion in acromegaly patients results in increased levels of IGF-1 expression, which causes the clinical manifestations of acromegaly. IGF-1 levels are attenuated by IGFBP3, and a polymorphism in the promoter of IGFBP3 is known to affect the circulating level of IGFBP3 protein. The aim of the study was to evaluate the association of the gene polymorphism with clinical features and surgery outcomes in acromegaly. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fendo.2018.00751
Publisher Site
http://dx.doi.org/10.3389/fendo.2018.00751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297192PMC
December 2018
7 Reads

A registry of acromegaly patients and one year following up in Taiwan.

J Formos Med Assoc 2019 Jan 3. Epub 2019 Jan 3.

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:

Background/purpose: The objectives of this study were to describe epidemiological data, treatment outcomes, and quality of life (QOL) of patients with acromegaly in Taiwan.

Methods: From 2013 to 2015, subjects with acromegaly were recruited through five medical centers. After enrollment, each patient was kept on observation for 1 year. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09296646183054
Publisher Site
http://dx.doi.org/10.1016/j.jfma.2018.12.017DOI Listing
January 2019
4 Reads

Daily life, needs and expectations of patients with acromegaly in France: An on-line survey.

Ann Endocrinol (Paris) 2018 Sep 25. Epub 2018 Sep 25.

Service d'endocrinologie, diabète-nutrition, CHU de Reims, 51092 Reims cedex, France.

Acromegaly can impair quality of life, but impact on patients' daily life, needs and expectations have been poorly explored.

Objectives: To better understand the impact of acromegaly on patients' daily life, and evaluate their needs and expectations.

Patients And Methods: An on-line questionnaire survey of acromegaly patient and relative community members was conducted on the Carenity website. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183124
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.08.006DOI Listing
September 2018
6 Reads

Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon.

Endocr Pathol 2019 Jan 4. Epub 2019 Jan 4.

Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.

Thyrotropin (TSH)-secreting pituitary tumors are the rarest functioning pituitary tumors. Nonetheless, they are not infrequently plurihormonal, as they may express/secrete hormones made by other pituitary cells derived from the Pit-1 lineage such as growth hormone (GH), prolactin (PRL), and α-subunit (αSU). However, adrenocorticotropin (ACTH) or gonadotropin secretion by such a tumor is exceptional. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12022-018-9562-3DOI Listing
January 2019
1 Read

How to Position Pasireotide LAR Treatment in Acromegaly.

J Clin Endocrinol Metab 2019 Jan 3. Epub 2019 Jan 3.

Department of Internal Medicine, Endocrinology section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands.

Context: Pasireotide long-acting release (LAR) is a somatostatin multi-receptor ligand and in the current consensus criteria pasireotide LAR is considered the second-line medical treatment of acromegaly. We present in this paper our recommendations to define the position of pasireotide LAR in the treatment of acromegaly and provide recommendations for the management of pasireotide-induced hyperglycemia.

Evidence Acquisition: Our recommendations are based on our experiences with the pasireotide LAR and pegvisomant (PEGV) combination study and the available basic or clinical papers published in peer-reviewed international journals on pasireotide LAR and acromegaly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-01979DOI Listing
January 2019
2 Reads

Endocytosis and degradation of pegvisomant and a potential new mechanism that inhibits the nuclear translocation of GHR.

J Clin Endocrinol Metab 2018 Dec 31. Epub 2018 Dec 31.

College of Animal Science and Technology, Jilin Agricultural University, China.

Context: Pegvisomant, a growth hormone receptor (GHR) antagonist, is a well-known drug that was designed to treat acromegaly. However, recent studies have indicated that the GHR is a "moonlighting" protein that may exhibit dual functions based on its localization in the plasma membrane and nucleus. In light of this finding, we explored whether pegvisomant is a potential "moonlighting" GHR antagonist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-02063DOI Listing
December 2018
2 Reads
6.209 Impact Factor

Surgical-pharmacological interactions in the treatment of acromegaly.

Expert Rev Endocrinol Metab 2019 Jan 29;14(1):35-42. Epub 2018 Dec 29.

c Experimental Endocrinology Unit , Hospital de Especialidades, Centro Medico Nacional S. XXI, IMSS , Mexico City , Mexico.

Introduction: Acromegaly requires a multimodal treatment approach that includes surgery by an expert pituitary neurosurgeon, pharmacological treatment with one or more of the available drugs and radiation therapy. These treatment alternatives are not mutually exclusive but rather complement each other when properly indicated in the individual patient. In this review, we summarize and analyze the available data concerning the choice of the surgical approach (microscopy vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17446651.2019.1559729DOI Listing
January 2019
2 Reads

Massive Pulmonary Embolism as the Initial Presentation of Acromegaly: Is Acromegaly a Hypercoagulable Condition?

Am J Case Rep 2018 Dec 29;19:1541-1545. Epub 2018 Dec 29.

Qatar University and Weill-Cornell College, Doha, Qatar.

BACKGROUND The clinical presentation in acromegaly is usually insidious, with headaches or visual disturbances being the most common symptoms. Previous studies have shown higher fibrinogen levels, lower protein C and S activity values, and enhanced platelet function in patients with acromegaly compared to a normal population. Nevertheless, the link between hypercoagulability and acromegaly is often overlooked and rarely reported in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.911572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322059PMC
December 2018
1 Read

Simpson-Golabi-Behmel syndrome in a 39-year-old male patient with suspected acromegaly-A case study.

Am J Med Genet A 2019 Feb 28;179(2):322-328. Epub 2018 Dec 28.

Pomeranian Medical University, Department of Endocrinology, Metabolic and Internal Diseases, Szczecin, Poland.

Simpson-Golabi-Behmel syndrome (SGBS) is a rare genetic condition and is inherited in an X-linked recessive manner. The disease is caused by a change in the nucleotide sequence of an X-linked gene encoding glypican 3, a protein belonging to the heparan-sulfate membrane proteoglycan family. SGBS case studies are almost entirely restricted to the pediatric population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajmg.a.61013DOI Listing
February 2019
2 Reads

Sodium Glucose Co-transporter Inhibitors in Patients with Acromegaly and Diabetes.

Authors:
Zaina Adnan

Trends Endocrinol Metab 2019 Feb 23;30(2):77-79. Epub 2018 Dec 23.

Department of Endocrinology and Metabolism, Clalit Medical Services, Haifa and Western Galilee District, Israel. Electronic address:

Acromegaly per se predisposes to diabetes. Somatostatin analogs (SSAs) have an overall neutral effect on glycemic control. However, a marked increase in hyperglycemia was observed recently since the introduction of pasireotide long-acting release (PAS-LAR). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10432760183021
Publisher Site
http://dx.doi.org/10.1016/j.tem.2018.11.007DOI Listing
February 2019
4 Reads

Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study.

Eur J Endocrinol 2019 Mar;180(3):201-211

Comenius University Faculty of Medicine, 5th Department of Internal Medicine, University Hospital Bratislava, Bratislava, Slovakia.

Introduction Impaired bone microarchitecture is involved in vertebral fracture (VF) development among acromegaly patients. Aim of the study Comparison of DXA-derived bone parameters, areal BMD (aBMD), trabecular bone score (TBS) and 3D-SHAPER parameters in acromegaly patients with healthy controls. Methods This cross-sectional study evaluated acromegaly patients and a control group of healthy subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EJE-18-0881DOI Listing
March 2019
1 Read

3D Facial Analysis in Acromegaly: Gender-Specific Features and Clinical Correlations.

Front Endocrinol (Lausanne) 2018 29;9:722. Epub 2018 Nov 29.

Department of Plastic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Quantitative investigations of facial changes in acromegaly are rare. A new imaging technique, three-dimensional (3D) stereophotography, can accurately quantify whole facial changes. We aimed to measure facial characteristics in acromegaly patients using 3D stereophotography, analyze gender-specific features, and explore clinical influencing factors. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fendo.2018.00722
Publisher Site
http://dx.doi.org/10.3389/fendo.2018.00722DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281698PMC
November 2018
14 Reads

Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas.

Clin Endocrinol (Oxf) 2019 Mar 15;90(3):457-467. Epub 2019 Jan 15.

Neuroendocrinology Clinic, Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

Objective: To evaluate the quality of life (QoL) in patients with pituitary adenomas in comparison with healthy Mexican population QoL scores.

Design & Measurements: Cross-sectional study using the short form 36 questionnaire (SF-36) in 175 patients with pituitary adenomas grouped by adenoma subtype and disease activity, and compared them with the healthy Mexican population normative QoL scores.

Patients: A total of 44 patients with non-functioning pituitary adenomas (NFPA), 48 with acromegaly, 53 with prolactinomas and 30 with Cushing disease (CD) were enrolled in this study. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cen.13915
Publisher Site
http://dx.doi.org/10.1111/cen.13915DOI Listing
March 2019
4 Reads

Cystatin C in adipose tissue and stimulation of its production by growth hormone and triiodothyronine in 3T3-L1 cells.

Mol Cell Endocrinol 2019 Feb 10;482:28-36. Epub 2018 Dec 10.

Division of Endocrinology, Diabetes & Clinical Nutrition, University Hospital, Zurich, Switzerland.

Cystatin C (CysC) is a marker for estimation of glomerular filtration rate (GFR). CysC levels may depend not only on clearance/GFR but possibly also on changes in production. Our studies on tissue distribution of CysC protein in mice showed that adipose tissue expresses significant amounts of CysC, suggesting that adipocytes could contribute to circulating CysC levels in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mce.2018.12.004DOI Listing
February 2019

Hypertension is Common in Patients with Newly Diagnosed Acromegaly and is Independently Associated with Renal Resistive Index.

High Blood Press Cardiovasc Prev 2019 Feb 7;26(1):69-75. Epub 2018 Dec 7.

Department of Radiology, University of Health Sciences-Adana Health Practice and Research Center, Dr. Mithat Özsan Bulvarı Kışla Mah, 4522 Sok, No: 1 Yüreğir, Adana, Turkey.

Introduction: There are conflicting results regarding the frequency of hypertension (HT) and values of related parameters in patients with acromegaly.

Aim: We aimed to determine the frequency of HT and values of its associated parameters in patients with acromegaly.

Methods: 57 patients with newly diagnosed acromegaly were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40292-018-0293-9DOI Listing
February 2019
2 Reads

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study.

Cancer Chemother Pharmacol 2019 Feb 8;83(2):375-385. Epub 2018 Dec 8.

Endocrinology, DiMI and CEBR, University of Genoa, Genoa, Italy.

Purpose: Octreotide SC depot is a novel, ready-to-use formulation administered via a thin needle. In a phase 1 study in healthy volunteers, this formulation provided higher bioavailability of octreotide with faster onset and stronger suppression of IGF-1 in healthy volunteers versus long-acting intramuscular (IM) octreotide. This phase 2 study evaluated the pharmacokinetics, efficacy, and safety of octreotide SC depot in patients with acromegaly and functioning NETs, previously treated with octreotide IM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3734-1DOI Listing
February 2019
1 Read

[Spontaneous remission of acromegaly and Cushing's disease in older patients. Report of two cases].

Rev Med Chil 2018 Jul;146(7):933-937

Departamento de Neurología y Neurocirugía, Hospital Clínico de la Universidad de Chile, Santiago, Chile.

Pituitary diseases such as acromegaly and Cushing's disease require surgical or medical therapy. In some functioning pituitary tumors, a spontaneous remission of hormonal hypersecretion is observed, mainly associated to apoplexy or pituitary infarction. We report the evolution of two female patients older than 70 years at the time of diagnosis, with multiple comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/s0034-98872018000700933DOI Listing
July 2018
10 Reads

Silent somatotropinomas.

Minerva Endocrinol 2018 Dec 7. Epub 2018 Dec 7.

Pathology Department, Hospital General Universitario de Alicante, Alicante, Spain.

Silent somatotroph pituitary neuroendocrine tumors (or silent growth hormone pituitary neuroendocrine tumors, SGH-PitNET) are neoplasias with positive immunostaining for growth hormone (GH), in patients with no signs and symptoms of acromegaly nor biochemical evidence of GH hypersecretion. From a clinical stand-point they are considered and managed as non-functioning pituitary tumors, since they usually come to evidence due to mass-effects (headache, visual impairment, hypopituitarism) or as asymptomatic pituitary incidentalomas. SGH-PitNET have deserved little attention in the medical literature, and no specific guidelines exist regarding their management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0391-1977.18.02946-2DOI Listing
December 2018
2 Reads